NKG2D ligand-targeting NK cells

**NKG2D ligand-targeting NK cells** are an investigational **CAR-NK cell therapy** in which autologous, allogeneic, or cord blood-derived natural killer cells are engineered to recognize tumor-expressed **NKG2D ligands**. In the earliest reported clinical format, NK cells were **mRNA-electroporated** to transiently express an NKG2D-ligand-directed chimeric antigen receptor for treatment of metastatic solid tumors, particularly metastatic colorectal cancer with peritoneal disease. Related later clinical programs used more durable genetically engineered **NKG2D CAR-NK** products, including constructs co-expressing **membrane-bound interleukin-15** to improve persistence. The therapeutic concept is to redirect NK-cell cytotoxicity toward malignant cells that upregulate stress ligands for NKG2D, thereby promoting tumor-cell killing and cytokine-mediated antitumor immunity. The name provided does not appear to identify a single branded commercial product, but rather a specific investigational NKG2D-ligand-directed NK-cell therapy concept used in early oncology trials.

Other names

CAR-NK cells targeting NKG2D ligandsNKG2D CAR-NK cellsNKG-2D CAR-NK cellsNKG 2D CAR-NK cellsNKG2D CAR mRNA-engineered natural killer cellsNKG-2D CAR mRNA-engineered natural killer cellsNKG 2D CAR mRNA-engineered natural killer cells